| 7.185 1.445 (25.17%) | 08-19 12:30 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 8.99 |
1-year : | 10.5 |
| Resists | First : | 7.69 |
Second : | 8.99 |
| Pivot price | 6.18 |
|||
| Supports | First : | 6.28 |
Second : | 5.4 |
| MAs | MA(5) : | 6.01 |
MA(20) : | 6.33 |
| MA(100) : | 5 |
MA(250) : | 3.94 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1  |
| %K %D | K(14,3) : | 38.4 |
D(3) : | 25.3 |
| RSI | RSI(14): 67.9 |
|||
| 52-week | High : | 7.69 | Low : | 2.27 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ MRVI ] has closed Bollinger Bands are 45.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 5.8 - 5.83 | 5.83 - 5.86 |
| Low: | 5.45 - 5.49 | 5.49 - 5.53 |
| Close: | 5.68 - 5.74 | 5.74 - 5.8 |
Maravai LifeSciences Holdings, Inc. is a life sciences company operating globally, supplying essential products that facilitate the advancement of drug therapies, diagnostics, innovative vaccines, and research into human diseases. Its diverse product line supports critical stages of biopharmaceutical development, featuring nucleic acids for both diagnostic and therapeutic applications, antibody-based solutions for detecting impurities in biopharmaceutical manufacturing, and tools for monitoring protein expression across different tissue types. The company conducts its operations through two distinct segments: Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment specializes in manufacturing and distributing products integral to gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics. This encompasses reagents utilized in the chemical synthesis, modification, labeling, and purification of DNA and RNA. Additionally, this division provides messenger RNA, oligonucleotides, their foundational building blocks, plasmid DNA, and the proprietary CleanCap capping technology. Meanwhile, the Biologics Safety Testing segment offers analytical products vital for developing biologic manufacturing processes. Its offerings include bespoke antibody and assay development services tailored to specific products, alongside HCP ELISA kits, various other ELISA kits for identifying bioprocess impurities and contaminants, ancillary reagents, and custom service solutions. Maravai's clientele spans biopharmaceutical companies, other life sciences and biopharmaceutical research firms, academic research institutions, and in vitro diagnostics companies. Incorporated in 2020, Maravai LifeSciences Holdings, Inc. maintains its headquarters in San Diego, California.
Fri, 14 Aug 2026
Maravai Lifesciences Holdings Inc (NASDAQ: MRVI) Stock Price, News & Analysis - Kalkine
Thu, 13 Aug 2026
Maravai LifeSciences (MRVI) group reports 4.0M shares, 2.72% beneficial stake - Stock Titan
Sat, 08 Aug 2026
Maravai LifeSciences (MRVI) Stock Faces Losses Despite Margin Recovery - simplywall.st
Fri, 07 Aug 2026
Maravai LifeSciences (MRVI) Releases Q2 2026 Earnings: Revenue Beats Estimates and Loss Narrows - Quiver Quantitative
Fri, 07 Aug 2026
Maravai LifeSciences Holdings (MRVI) Stock Analysis: Navigating Challenges with Biotech Innovation - DirectorsTalk Interviews
Fri, 07 Aug 2026
Maravai LifeSciences Holdings Inc (MRVI) (Q2 2026) Earnings Call - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 148 (M) |
| Shares Float | 102 (M) |
| Held by Insiders | 13.7 (%) |
| Held by Institutions | 90.3 (%) |
| Shares Short | 9,270 (K) |
| Shares Short P.Month | 8,650 (K) |
| EPS | -0.53 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.42 |
| Profit Margin | -37.1 % |
| Operating Margin | -29.4 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 8.5 % |
| Gross Profit (p.s.) | 0.5 |
| Sales Per Share | 1.41 |
| EBITDA (p.s.) | -0.13 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -13.54 |
| PEG Ratio | 0 |
| Price to Book value | 5.01 |
| Price to Sales | 5.06 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|